The role of tocilizumab in the treatment of rheumatoid arthritis
More details
Hide details
Online publication date: 2008-07-09
Reumatologia 2008;46(3):140-150
Interleukin 6 (IL-6) is a pleiotropic cytokine displaying multiple biological activities. Dysregulation of IL-6 appears to contribute to both systemic and local rheumatoid arthritis (RA) symptoms. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6-receptor. Clinical efficacy and safety of tocilizumab in RA are discussed in this review. According to data available so far tocilizumab has proved its ability to reduce disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of this chronic autoimmunological inflammatory process.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top